Crohn's disease goes along with an alteration of the quality of life, even in remission and has a negative impact on stress management linked to the pain and the health. Conversely, stress and psychological variables play a significant role in the pathogenesis of this disease. These interrelations reflects the link between the brain and the digestive tract, called brain-gut axis. The autonomic nervous system (ANS) is the neurological interface, relaying in a bidirectional way, informations between the digestive tract and the central nervous system (CNS).

Visceral information can thus modulate the functionnement of CNS's areas involved in pain management but also in the management of emotional and cognitive behaviours. Yet, numerous work demonstrate the existence of a dysfunction of the ANS during Crohn's disease, with a dysautonomia of the sympatho-vagal balance.

Human brain respond by advance before and during the application of a painful stimulus that enable the organism to regulate its nociceptive system in order to handle the aversive stimulus incoming, via the activation of brin areas managing the pain, or the raise of pain awareness.

The uncertain and not predictable nature of a painful crisis and/or an inflammatory relapse in a chronic disease like Crohn's disease can be the origin of an anticipating apprehension and anxiety, that could influence visceral perception (increasing it). Nevertheless, only few studies exists about the differential role of certain or uncertain anticipation of the pain, despite the fact that they are associated to different emotional, cognitive and behavioral responses, and the effect of anticipation on painful visceral perception, have not yet been studied for parents in remission of Crohn's disease.

The main goal is to search during certain and uncertain visceral anticipation, induced by distension of an intra-rectal balloon for persons suffering from Crohn's disease in remission, compared to control subjects, with an MRI functional study

Inclusion Criteria:

• For patients :

  • Patients over 18 years and less than 60 years.
  • Right-handed.
  • Diagnosis of Crohn's disease established on clinical biological, endoscopic and anatomopathological criteria.
  • Ideal localization and/or diarrhea of Crohn's Disease, with an absence of rectal or anoperineal ravages past or presents in order to not do distension on rectal/ and anoperineal lesions.
  • Crohn's disease treatment authorize : 5-aminosalicylates since at least 4 weeks with a stable dose since at least 2 weeks ; immunosuppressive drugs since at least 12 weeks with a stable dose since at least 4 weeks ; anti-TNF since at least 3 months with a stable dose since at least 1 month ; absence of corticosteroid treatment since at least 15 days.
  • Clinical remission : Crohn's Disease Activity Index (CDAI) < 150 (Best 1976) and biological : normal CRP and faecal calprotectin < 100 g/g.
  • Patient able to understand and follow necessary commissions for the conduct of the clinical trial, and that have given his free written consent for this study.
  • Registered to a French social security.
  • The person won't be allow to participate simultaneously to another study and there won't be an exclusion period to participation to a clinical or therapeutic trial at the end of this study.

• For healthy volunteers

  • Patients over 18 years and less than 60 years.
  • Right-handed.
  • Paired with patients for sex and age.
  • Absence of digestive surgical or medical history except appendectomy, hysterectomy, cholecystectomy, inguinal hernia cure and/or femoral.
  • Absence of digestive symptomatology searched while a standardized interrogation.
  • Clinical digestive exam normal.
  • The person won't be allow to participate simultaneously to another study and there won't be an exclusion period to. participation to a clinical or therapeutic trial at the end of this study.
  • Registered to a French social security.
  • Registered to the national file of persons participating to biomedicals searches without direct individual profit.

Exclusion Criteria:

• Subjet under 18 years and more than 60 years.
• Counter-argument for MRI : presence of intra-corporeal ferro-magnetic particles, claustrophobia.
• Existence of a severe condition on general level (cardiac, respiratory, hematological, renal, hepatic, cancerous).
• Existence of an organic digestive affection (gastritis, gallstones, duodenal ulcer, megacolon, inflammatory colitis).
• Existence or history malignant gastrointestinal condition.
• History of abdominal digestive surgery except appendectomy, hysterectomy, cure of inguinal hernia)
• Recto-anal or périneal active pathology (haemorrhoid , anal fissure …).
• Presence of arectal fecal impaction.
• Patient included in an other clinical or therapeutic trial.
• Patient treated by a drug sensitive to modify sensitivity and/or digestive motor function.
• Patient regularly receiving psychotropic drugs (anxiolytics, sedatives, antidepressants, neuroleptics).
• Patient with a pathology that could modify visceral sensitivity like diabetes or neurodegenerative diseases.
• Persons concerned by articles L1121-5 to L1121-8 of CSP.

Patients with Crohn's disease